Spotlight Innovation Inc. (OTCMKTS:STLT) Files An 8-K Other Events
Item 8.01 Other Events.
On June 15, 2017, Spotlight Innovation Inc. issued a Company
Overview that it plans to present to potential and existing
investors. A copy of this Company Overview is furnished as
Exhibit 99.1 hereto and is incorporated herein by reference. The
Company Overview is also posted on Spotlight Innovation Inc.’s
website at http://ir.spotlightinnovation.com/.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibit
The following document is furnished as an Exhibit to Item 8.01
hereof:
|
Exhibit |
|
|
99.1 |
STLT Corporate Presentation Summer 2017. |
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
SPOTLIGHT INNOVATION INC. |
|||
|
Dated: June 16, 2017 |
By: |
/s/ John William Pim |
|
|
John William Pim |
|||
|
Chief Financial Officer |
EXHIBIT INDEX
Item 9.01 Financial Statements and Exhibits.
(d) Exhibit
The following document is furnished as an Exhibit
About Spotlight Innovation Inc. (OTCMKTS:STLT)
Spotlight Innovation Inc., formerly American Exploration Corporation, is a bioscience company. The Company is focused on acquiring the rights, through acquisition, license or otherwise, to various technologies. The Company is engaged in identifying and targeting technology candidates, including cancer drugs and treatment therapies for various disease states; drug and related treatment therapies for various infectious diseases, and other technology candidates. The Company focuses on diseases that are rare, which are known as orphan diseases, or new or common but underserved, such as feline chronic kidney disease. As of December 31, 2015, the Company had three subsidiaries: Celtic Biotech Iowa, Inc., CDT Veterinary Therapeutics, Inc. and Memcine Pharmaceuticals, Inc. Through its subsidiary, Celtic Biotech Iowa, Inc., it develops a range of drug candidates, such as Crotoxin, Cardiotoxin, VRCTC310 and Crotamine. Through its subsidiary, Memcine Pharmaceuticals, Inc., it offers Immunoplex.